EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of type II NADH dehydrogenase in Mycobacterium tuberculosis reveals collateral vulnerability in the electron transport chain

Vien Q T Ho iD, Vincent Fontaine, Ernesto Anoz-Carbonell iD, Kamel Djaout iD, Clement Vigier, Leo Faion iD, Samsher Singh iD, Sushovan Dam, Jonathan Chatagnon iD, Stéphanie Slupek, Rudy Antoine iD, Aurélie Chauffour iD und 8 weitere

Antimicrobial Agents and Chemotherapy · 04.11.2026 · 70 (11)

DOI: 10.1128/aac.00756-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.11.2026. Verfasst von Vien Q T Ho und 19 weiteren Autor:innen. Beteiligte Einrichtung: University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017, Center for Infection and Immunity of Lille (CIIL), Lille, Franc…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, NADH Dehydrogenase, Antitubercular Agents. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ANR-JCJC, ANRS-MIE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To sustain the anti-tuberculosis drug development pipeline, novel antibiotics must be developed both as standalone agents and as components of future combination regimens. To this end, tricyclic-spirolactams (TriSLa)-based inhibitors of mycobacterial type II NADH dehydrogenase (Ndh-2) represent a promising novel class of antibiotics, though activity is carbon source dependent. Initial studies established an enhanced understanding of the impact of TriSLa on mycobacteria using metabolomics and transcriptomics. Then, CRISPRi chemical-genetics and extensive in vitro TriSLa-combination studies showed that Ndh-2 inhibition resulted in rendering other components of the electron transport chain vulnerable, even in conditions when TriSLa was inactive alone. Finally, identified in vitro synergistic TriSLa-antibiotic combinations were validated to also give modestly improved in vivo efficacy. Together, this work expands our understanding of how Ndh-2 inhibition impacts bacterial physiology and reveals how it sensitizes the bacterium to electron transport chain inhibitors, providing a foundation for future TriSLa-based combination regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisNADH DehydrogenaseAntitubercular AgentsElectron TransportMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Mycobacterium tuberculosisNADH dehydrogenasedrug combinationrespiration chainsynergy

Substanzen

NADH DehydrogenaseAntitubercular AgentsNADH dehydrogenase II

Autor:innen und Institutionen

  • University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017, Center for Infection and Immunity of Lille (CIIL), Lille, France.
  • Centre d'Immunologie et des Maladies Infectieuses, CIMI, Sorbonne Université, CNRS, Inserm, Paris, France.
  • University Lille, Inserm, Institut Pasteur de Lille, U1177-Drugs and Molecules for Living Systems, Lille, France.
  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
  • Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, AP-HP, Sorbonne Université, Paris, France.
  • Singapore Centre for Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University, Singapore, Singapore.

ORCID-Profile: Vien Q T Ho, Ernesto Anoz-Carbonell, Kamel Djaout, Leo Faion, Samsher Singh, Jonathan Chatagnon, Rudy Antoine, Aurélie Chauffour, Benoit Deprez, Kevin Pethe, Nicolas Veziris, Nicolas Willand, Robert Jansen, Baptiste Villemagne, Ruben C Hartkoorn

Förderung

  • ANR-JCJC
  • ANRS-MIE

Zitieren

APA

Ho, V. Q. T., Fontaine, V., Anoz-Carbonell, E., Djaout, K., Vigier, C., Faion, L., Singh, S., Dam, S., Chatagnon, J., Slupek, S., Antoine, R., Chauffour, A., Aubry, A., Deprez, B., Pethe, K., Veziris, N., Willand, N., Jansen, R., Villemagne, B., & Hartkoorn, R. C. (2026). Inhibition of type II NADH dehydrogenase in Mycobacterium tuberculosis reveals collateral vulnerability in the electron transport chain. Antimicrobial Agents and Chemotherapy, 70(11). https://doi.org/10.1128/aac.00756-26

Vancouver

Ho VQT, Fontaine V, Anoz-Carbonell E, Djaout K, Vigier C, Faion L, et al. Inhibition of type II NADH dehydrogenase in Mycobacterium tuberculosis reveals collateral vulnerability in the electron transport chain. Antimicrobial Agents and Chemotherapy. 2026;70(11). doi:10.1128/aac.00756-26

BibTeX
@article{Ho2026,
  author = {Ho, Vien Q T and Fontaine, Vincent and Anoz-Carbonell, Ernesto and Djaout, Kamel and Vigier, Clement and Faion, Leo and Singh, Samsher and Dam, Sushovan and Chatagnon, Jonathan and Slupek, Stéphanie and Antoine, Rudy and Chauffour, Aurélie and Aubry, Alexandra and Deprez, Benoit and Pethe, Kevin and Veziris, Nicolas and Willand, Nicolas and Jansen, Robert and Villemagne, Baptiste and Hartkoorn, Ruben C},
  title = {Inhibition of type II NADH dehydrogenase in Mycobacterium tuberculosis reveals collateral vulnerability in the electron transport chain},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {11},
  doi = {10.1128/aac.00756-26}
}
Kostenlos starten →